{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-256458","form_type":"8-K","ticker":"SNDX","cik":"0001395937","company_name":"Syndax Pharmaceuticals Inc","filed_at":"2026-06-04T11:16:36+00:00","discovered_at":"2026-06-04T11:20:00.321054+00:00","generated_at":"2026-06-04T11:20:08.159075+00:00","sec_items":["1.01","2.03","3.02","8.01","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Syndax raises $250M via 2.25% convertible notes due 2031; conversion price at 35% premium","bullets":["$250M aggregate principal, 2.25% interest, semiannual payments starting Dec 15, 2026, maturing June 15, 2031.","Net proceeds ~$243M after fees; used for general corporate purposes including R&D, commercialization, and BD.","Initial conversion rate 40.3894 shares per $1,000 principal, equivalent to ~$24.76/share (35% premium over June 3 closing).","Notes are senior unsecured; callable only after June 20, 2029 if stock price exceeds 130% of conversion price.","Conversion permitted upon certain stock price thresholds or specified corporate events; company may settle in cash, stock, or mix."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-256458","json":"https://secwatch.observer/filing/0001193125-26-256458.json","markdown":"https://secwatch.observer/filing/0001193125-26-256458.md","text":"https://secwatch.observer/filing/0001193125-26-256458.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1395937/000119312526256458/0001193125-26-256458-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1395937/000119312526256458/d65010d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T11:20:08.159075+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e0414df17aae17fed0316c2e7b88c12c0100b1e1","claim":"Syndax Pharmaceuticals Inc issued convertible note to certain investors for $250.0 million aggregate principal amount.","evidence_excerpt":"the Company will issue $250.0 million aggregate principal amount of 2.25% Convertible Senior Notes due 2031","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1395937/000119312526256458/0001193125-26-256458-index.htm","confidence":0.9,"family_label":"Equity Issuances","details":[{"label":"Security","value":"convertible note"},{"label":"Purchaser","value":"certain investors"},{"label":"Consideration","value":"$250.0 million aggregate principal amount"}],"fact_type":"equity_issuance"},{"claim_id":"8aaefc5634505669ec7e92567af15e450e344b98","claim":"Syndax Pharmaceuticals Inc entered into Indenture with U.S. Bank Trust Company, National Association valued at $250.0 million aggregate principal amount of 2.25% Convertible Senior Notes due 2031 (effective 2026-06-03).","evidence_excerpt":"On June 3, 2026, Syndax Pharmaceuticals, Inc. (the “ Company ”) entered into privately negotiated subscription agreements (the “ Subscription Agreements ”) with certain investors, pursuant to which the Company will issue $250.0 million aggregate principal amount of 2.25% Convertible Senior Notes due 2031 (the “ Notes ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1395937/000119312526256458/0001193125-26-256458-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"notes offering"},{"label":"Counterparty","value":"U.S. Bank Trust Company, National Association"},{"label":"Value","value":"$250.0 million aggregate principal amount of 2.25% Convertible Senior Notes due 2031"},{"label":"Effective","value":"2026-06-03"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}